Compile Data Set for Download or QSAR
Report error Found 9 Enz. Inhib. hit(s) with all data for entry = 2966
TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172452(US9090625, 4 | US9260450, 4 | US9938289, 4 | US202...)
Affinity DataIC50: 1.92nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172455(US9090625, 7 | US9260450, 7 | US9938289, 7 | US202...)
Affinity DataIC50: 6.65nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172457(US9090625, 12 | US9260450, 12 | US9938289, 12 | US...)
Affinity DataIC50: 7.94nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172458(US9090625, 13 | US9260450, 13 | US9938289, 13 | US...)
Affinity DataIC50: 18.9nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172453(US9090625, 5 | US9260450, 5 | US9938289, 5 | US202...)
Affinity DataIC50: 21.8nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172449(US9090625, 1 | US9260450, 1 | US9938289, 1 | US202...)
Affinity DataIC50: 23.4nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172454(US9090625, 6 | US9260450, 6 | US9938289, 6 | US202...)
Affinity DataIC50: 35.2nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172450(US9090625, 2 | US9260450, 2 | US9938289, 2 | US202...)
Affinity DataIC50: 93.9nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Fbm Therapeutics

US Patent
LigandPNGBDBM172451(US9090625, 3 | US9260450, 3 | US9938289, 3 | US202...)
Affinity DataIC50: 108nMAssay Description:ALK-5 kinase assay methods have been described in the art (see e.g., Laping et al. (2002) Mol. Pharmacol. 2002; 62: 58-62). The compounds named in th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2020
Entry Details
Go to US Patent